Completed PHASE3 INTERVENTIONAL 2-arm NCT01535859

Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers

A Randomised Controlled Trial of Cabergoline Prophylaxis for Ovarian Hyperstimulation Syndrome in IVF Cycles and Derivation of Biomarkers for OHSS.

Sponsor: KK Women's and Children's Hospital

Conditions Ovarian Hyperstimulation Syndrome

Interventions Cabergoline Placebo

Updated 7 times since 2017 Last updated: Aug 5, 2018 Started: Apr 30, 2012 Primary completion: Jun 30, 2015 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Ovarian Hyperstimulation Syndrome and is currently completed. KK Women's and Children's Hospital leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2018 — Jan 2021 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jul 2018 — Sep 2018 [monthly]

Unknown Status PHASE3

Status: Active Not Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Jul 2018 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

KK Women's and Children's Hospital

Data source: KK Women's and Children's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore